Plasma sarcosine does not distinguish early and advanced stages of prostate cancer
Plasma sarcosine does not distinguish early and advanced stages of prostate cancer
复制标题
DOI：
10.7196/samj.5768
复制
发表时间：
2012-08-01
期刊：
影响因子：
--
通讯作者：
Harvey, J
中科院分区：
文献类型：
--
作者：
Bohm, L;Serafin, A M;Harvey, J
导论.前列腺特异性抗原（PSA）诊断前列腺癌容易出错，不能区分良性前列腺增生（BPH）和恶性前列腺疾病，也不能区分侵袭性和惰性类型。我们采用气相色谱/质谱联用技术（GC/MS）检测了328例癌症患者血清中的肌氨酸（N-甲基甘氨酸），并探讨其与早期（T1/T2期）和晚期（T3/T4期）疾病的相关性。男性对照患者的血清肌氨酸范围为1.7 μ mol/l至4.8 μ mol/l。在前列腺癌患者中，肌氨酸的范围为2.8 μ mol/l至20.1 μ mol/l。以肌氨酸/丙氨酸比值表示，血清对照值为9.4 +/- 5.5x10（-3）（平均值+/- SD），而诊断为T1、T2、T3和T4前列腺肿瘤的患者分别为21.6 +/- 9.0、28.5 +/- 16.6、22.7 +/- 7.7和22.2 +/- 11.0。T1、T2、T3和T4患者之间的微小差异无统计学显著性（p=0.51）。然而，常规PSA标志物与这些患者的T分期显著相关（r=0.63; p
Introduction. Diagnosis of prostate cancer by prostate specific antigen (PSA) is error-prone and cannot distinguish benign prostatic hyperplasia (BPH) from malignant disease, nor identify aggressive and indolent types.Methods. We determined serum sarcosine (N-methylglycine) in 328 cancer patients by gas chromatography (GC)/mass spectroscopy (MS) and searched for correlations with early (stage T1/T2) and advanced (stage T3/T4) disease.Results. Serum sarcosine of male control patients ranged from 1.7 mu mol/l to 4.8 mu mol/l. In prostate cancer patients, sarcosine ranged from 2.8 mu mol/l to 20.1 mu mol/l. Expressed as the sarcosine/alanine ratio, serum control values were 9.4 +/- 5.5x10(-3) (mean +/- SD) compared with 21.6 +/- 9.0; 28.5 +/- 16.6; 22.7 +/- 7.7 and 22.2 +/- 11.0 for patients diagnosed with T1, T2, T3 and T4 prostate tumours, respectively. The small differences between T1, T2, T3 and T4 patients were not statistically significant (p=0.51). However, the conventional PSA marker significantly correlated with T stage in these patients (r=0.63; p